Nuclear Medicine market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 10.19 Billion
CAGR (2026-2031)	11.27%
Fastest Growing Segment	Therapeutic Nuclear Medicine
Largest Market	North America
Market Size (2031)	USD 19.34 Billion

Market Overview

The Global Nuclear Medicine market will grow from USD 10.19 Billion in 2025 to USD 19.34 Billion by 2031 at a 11.27% CAGR. Nuclear medicine constitutes a specialized medical sector involving the use of radiopharmaceuticals to assess physiological functions and treat diseases through targeted molecular interventions. The market is fundamentally supported by the rapidly aging global population and the concomitant rise in chronic conditions such as cancer and cardiovascular disorders, which drive the necessity for high-precision diagnostic and therapeutic tools. These demographic and epidemiological factors ensure a sustained demand for nuclear imaging and radionuclide therapies, distinct from transient technological trends.

However, the industry faces a significant impediment regarding the reliability of its supply chain, particularly the consistent availability of short-lived radioisotopes used in diagnostics. The production of these critical materials relies heavily on a limited number of aging research reactors, creating vulnerabilities to logistical disruptions. According to Nuclear Medicine Europe, in late 2024, unanticipated reactor maintenance issues were projected to cause supply shortages of up to 40% for essential diagnostic isotope generators, highlighting the fragility of the global distribution network.

Key Market Drivers

The rapid expansion of theranostics and precision medicine applications is acting as a primary catalyst for market growth, fundamentally shifting the sector from purely diagnostic imaging to integrated therapeutic solutions. This approach, which pairs diagnostic biomarkers with therapeutic radioisotopes, has gained immense commercial traction, particularly in oncology for treating prostate and neuroendocrine cancers. The commercial viability of this driver is evident in the performance of leading radioligand therapies; according to Novartis, October 2024, in the 'Q3 2024 Results', global sales for its prostate cancer therapy, Pluvicto, reached $386 million for the quarter, reflecting a 50% growth rate compared to the previous year. Consequently, major pharmaceutical entities are aggressively entering the space to capitalize on this demand. For instance, according to Bristol Myers Squibb, February 2024, in the 'Bristol Myers Squibb Completes Acquisition of RayzeBio' press release, the company invested approximately $4.1 billion to acquire RayzeBio, specifically to gain access to their pipeline of actinium-based radiopharmaceutical therapeutics, validating the industry’s pivot toward targeted alpha therapies.

Simultaneously, improvements in the radiopharmaceutical supply chain and isotope production are emerging to mitigate the historical reliance on aging nuclear reactors. To address the fragility of the global distribution network and the scarcity of alpha-emitters required for next-generation therapies, the industry is seeing a surge in investment dedicated to alternative production methods such as particle accelerators. This structural shift is exemplified by recent capital inflows into European production infrastructure. According to PanTera NV, September 2024, in the 'PanTera Secures €93 Million in Series A Funding' announcement, the company raised 93 million Euros to accelerate the construction of a commercial-scale facility in Belgium dedicated to producing Actinium-225. These advancements in manufacturing capacity are critical for ensuring a stable supply of isotopes, thereby reducing logistical vulnerabilities and supporting the sustainable commercialization of new nuclear medicine agents.

Download Free Sample Report

Key Market Challenges

The primary obstacle impeding the growth of the Global Nuclear Medicine market is the persistent instability of its supply chain, particularly regarding the production of short-lived radioisotopes. Unlike conventional pharmaceuticals, isotopes such as Molybdenum-99 cannot be stockpiled due to their rapid radioactive decay, necessitating a flawless "just-in-time" global distribution network. This system is currently anchored by a diminishing fleet of aging research reactors, which are increasingly prone to unscheduled maintenance and structural failures. When these critical facilities go offline, the immediate scarcity of diagnostic agents forces healthcare providers to postpone or cancel procedures, directly curbing revenue generation and procedure volumes.

This operational unreliability significantly hampers market expansion by eroding confidence among physicians and hospital administrators. Faced with unpredictable supply cycles, medical professionals may divert patients to alternative diagnostic modalities like MRI or CT, thereby stalling the adoption of nuclear imaging techniques. The severity of this dependency is acute in major markets; according to the Society of Nuclear Medicine and Molecular Imaging, in 2024, the United States relied on foreign imports for over 80% of its Technetium-99m supply, leaving the industry highly vulnerable to international logistical disruptions.

Key Market Trends

The expansion of radiopharmaceutical applications into neurology is fundamentally reshaping the market, driven by the commercialization of disease-modifying therapies for Alzheimer’s disease that mandate precise molecular imaging. Unlike the sector’s historical reliance on oncology, this trend is anchored in the critical role of amyloid-beta positron emission tomography (PET) scans for patient qualification and treatment monitoring. This clinical necessity has catalyzed an immediate surge in diagnostic volume, validating the shift toward non-oncological indications. For instance, according to Fierce Pharma, February 2025, in the 'Eisai execs flag Leqembi expansion phase' article, Eisai reported a 45% increase in amyloid beta PET testing volume in the United States during the final quarter of 2024, directly correlating therapeutic adoption with diagnostic demand.

The rising prominence of Contract Development and Manufacturing Organizations (CDMOs) is simultaneously emerging as a structural pillar of the industry, as stakeholders seek to mitigate supply chain fragility through consolidated, high-capacity infrastructure. Investors and major healthcare entities are increasingly valuing vertically integrated manufacturers that can guarantee the reliability of complex isotope production and global distribution. This escalation in value is evident in recent capital market activities; according to Curium Pharma, November 2025, in the 'CapVest recapitalizes Curium to accelerate its growth strategy' press release, the company secured a recapitalization transaction valuing the business at approximately $7 billion, underscoring the premium placed on scalable manufacturing capabilities.

Segmental Insights

The Therapeutic Nuclear Medicine segment represents the fastest-growing category within the global market, driven by the successful commercialization of targeted radioligand therapies. This growth is underpinned by recent product approvals from regulatory agencies like the U.S. Food and Drug Administration that address specific oncological indications, including prostate and neuroendocrine cancers. The segment benefits significantly from the clinical shift toward precision medicine, where radioactive isotopes are used to treat diseased cells with high specificity. Continued research into novel isotopes and expanding clinical applications further reinforces the accelerated expansion of this market sector.

Regional Insights

North America maintains a dominant position in the global nuclear medicine market due to its developed healthcare infrastructure and substantial investment in medical research. The region benefits from the presence of major pharmaceutical companies that focus on developing novel radiopharmaceuticals. Furthermore, the United States Food and Drug Administration supports market expansion through established regulatory frameworks that facilitate product approvals. The high volume of diagnostic and therapeutic procedures performed for oncology and cardiology applications further strengthens the demand within the United States and Canada, ensuring sustained regional leadership.

Recent Developments

In December 2024, Siemens Healthineers finalized the acquisition of the molecular imaging business from Novartis, specifically the diagnostic division of Advanced Accelerator Applications. The transaction, valued at over €200 million, integrated a comprehensive European network of cyclotrons into the company's existing PET radiopharmacy operations. This strategic move was designed to secure a reliable supply of essential radioactive isotopes used in cancer diagnostics across Europe. Concurrently, the companies established a collaboration to ensure the continued production of nuclear isotopes required for the manufacturing of radioligand therapies, strengthening the supply chain for critical nuclear medicine products.
In July 2024, Telix Pharmaceuticals announced that the U.S. Food and Drug Administration had accepted its New Drug Application for a novel prostate cancer imaging product. The submission covers a proprietary cold kit designed for the preparation of a PSMA-PET imaging agent, which aims to facilitate wider geographic access to advanced diagnostic tools. If approved, this product would enable nuclear pharmacies to produce the imaging agent with greater flexibility, thereby extending the reach of precise cancer detection to underserved regions. This regulatory progression represents a key step in the company's effort to enhance the availability of psma-targeted diagnostics.
In April 2024, Novartis received approval from the U.S. Food and Drug Administration for a significant label expansion of its radioligand therapy, Lutathera. The regulatory decision authorized the use of the drug for pediatric patients aged 12 years and older suffering from somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This milestone established the therapy as the first radiopharmaceutical specifically approved for this adolescent population, based on positive results from the NETTER-P trial. The expansion underscores the company's strategy to broaden the clinical application of its nuclear medicine portfolio to younger patients with rare cancers.
In January 2024, Lantheus Holdings entered into multiple strategic agreements with Perspective Therapeutics to advance the development of innovative radiopharmaceuticals. The collaboration granted Lantheus an option to exclusively license a clinical-stage alpha therapy designated for the treatment of neuroendocrine tumors, as well as an option to co-develop therapeutic candidates targeting prostate cancer. To support these initiatives, Lantheus agreed to provide an upfront payment and make an equity investment of approximately $33 million in the partner company. This partnership aims to leverage proprietary technology to expand the pipeline of targeted alpha therapies for oncological applications.

Key Market Players

Cardinal Health, Inc.
Curium SAS
GE Healthcare, Inc.
Novartis AG
Lantheus Medical Imaging, Inc.
Bayer AG
Bracco Imaging S.p.A
Nordion Inc.
Isotopia Molecular Imaging Limited
NorthStar Medical Radioisotopes, LLC

By Type	By Diagnostic Nuclear Medicine	By Therapeutic Nuclear Medicine	By Application	By End User	By Region
Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine	SPECT & PET Radiopharmaceuticals	Beta Emitters Alpha Emitters & Brachytherapy Isotopes	Oncology Cardiology Neurology Others	Hospitals & Clinics Diagnostic Centers Academic & Research Institutions Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Nuclear Medicine market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nuclear Medicine market, By Type:

Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine

Nuclear Medicine market, By Diagnostic Nuclear Medicine:

SPECT & PET Radiopharmaceuticals

Nuclear Medicine market, By Therapeutic Nuclear Medicine:

Beta Emitters
Alpha Emitters & Brachytherapy Isotopes

Nuclear Medicine market, By Application:

Oncology
Cardiology
Neurology
Others

Nuclear Medicine market, By End User:

Hospitals & Clinics
Diagnostic Centers
Academic & Research Institutions
Others

Nuclear Medicine market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nuclear Medicine market.

Available Customizations:

Global Nuclear Medicine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Nuclear Medicine market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nuclear Medicine market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type (Diagnostic Nuclear Medicine & Therapeutic Nuclear Medicine)

5.2.2. By Diagnostic Nuclear Medicine (SPECT & PET Radiopharmaceuticals)

5.2.3. By Therapeutic Nuclear Medicine (Beta Emitters, Alpha Emitters & Brachytherapy Isotopes)

5.2.4. By Application (Oncology, Cardiology, Neurology, Others)

5.2.5. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Nuclear Medicine market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Diagnostic Nuclear Medicine

6.2.3. By Therapeutic Nuclear Medicine

6.2.4. By Application

6.2.5. By End User

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Nuclear Medicine market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By Diagnostic Nuclear Medicine

6.3.1.2.3. By Therapeutic Nuclear Medicine

6.3.1.2.4. By Application

6.3.1.2.5. By End User

6.3.2. Canada Nuclear Medicine market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By Diagnostic Nuclear Medicine

6.3.2.2.3. By Therapeutic Nuclear Medicine

6.3.2.2.4. By Application

6.3.2.2.5. By End User

6.3.3. Mexico Nuclear Medicine market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type

6.3.3.2.2. By Diagnostic Nuclear Medicine

6.3.3.2.3. By Therapeutic Nuclear Medicine

6.3.3.2.4. By Application

6.3.3.2.5. By End User

7. Europe Nuclear Medicine market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Diagnostic Nuclear Medicine

7.2.3. By Therapeutic Nuclear Medicine

7.2.4. By Application

7.2.5. By End User

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Nuclear Medicine market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Diagnostic Nuclear Medicine

7.3.1.2.3. By Therapeutic Nuclear Medicine

7.3.1.2.4. By Application

7.3.1.2.5. By End User

7.3.2. France Nuclear Medicine market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By Diagnostic Nuclear Medicine

7.3.2.2.3. By Therapeutic Nuclear Medicine

7.3.2.2.4. By Application

7.3.2.2.5. By End User

7.3.3. United Kingdom Nuclear Medicine market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Diagnostic Nuclear Medicine

7.3.3.2.3. By Therapeutic Nuclear Medicine

7.3.3.2.4. By Application

7.3.3.2.5. By End User

7.3.4. Italy Nuclear Medicine market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type

7.3.4.2.2. By Diagnostic Nuclear Medicine

7.3.4.2.3. By Therapeutic Nuclear Medicine

7.3.4.2.4. By Application

7.3.4.2.5. By End User

7.3.5. Spain Nuclear Medicine market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type

7.3.5.2.2. By Diagnostic Nuclear Medicine

7.3.5.2.3. By Therapeutic Nuclear Medicine

7.3.5.2.4. By Application

7.3.5.2.5. By End User

8. Asia Pacific Nuclear Medicine market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Diagnostic Nuclear Medicine

8.2.3. By Therapeutic Nuclear Medicine

8.2.4. By Application

8.2.5. By End User

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Nuclear Medicine market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By Diagnostic Nuclear Medicine

8.3.1.2.3. By Therapeutic Nuclear Medicine

8.3.1.2.4. By Application

8.3.1.2.5. By End User

8.3.2. India Nuclear Medicine market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By Diagnostic Nuclear Medicine

8.3.2.2.3. By Therapeutic Nuclear Medicine

8.3.2.2.4. By Application

8.3.2.2.5. By End User

8.3.3. Japan Nuclear Medicine market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By Diagnostic Nuclear Medicine

8.3.3.2.3. By Therapeutic Nuclear Medicine

8.3.3.2.4. By Application

8.3.3.2.5. By End User

8.3.4. South Korea Nuclear Medicine market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type

8.3.4.2.2. By Diagnostic Nuclear Medicine

8.3.4.2.3. By Therapeutic Nuclear Medicine

8.3.4.2.4. By Application

8.3.4.2.5. By End User

8.3.5. Australia Nuclear Medicine market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type

8.3.5.2.2. By Diagnostic Nuclear Medicine

8.3.5.2.3. By Therapeutic Nuclear Medicine

8.3.5.2.4. By Application

8.3.5.2.5. By End User

9. Middle East & Africa Nuclear Medicine market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Diagnostic Nuclear Medicine

9.2.3. By Therapeutic Nuclear Medicine

9.2.4. By Application

9.2.5. By End User

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Nuclear Medicine market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Diagnostic Nuclear Medicine

9.3.1.2.3. By Therapeutic Nuclear Medicine

9.3.1.2.4. By Application

9.3.1.2.5. By End User

9.3.2. UAE Nuclear Medicine market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Diagnostic Nuclear Medicine

9.3.2.2.3. By Therapeutic Nuclear Medicine

9.3.2.2.4. By Application

9.3.2.2.5. By End User

9.3.3. South Africa Nuclear Medicine market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By Diagnostic Nuclear Medicine

9.3.3.2.3. By Therapeutic Nuclear Medicine

9.3.3.2.4. By Application

9.3.3.2.5. By End User

10. South America Nuclear Medicine market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type

10.2.2. By Diagnostic Nuclear Medicine

10.2.3. By Therapeutic Nuclear Medicine

10.2.4. By Application

10.2.5. By End User

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Nuclear Medicine market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

10.3.1.2.2. By Diagnostic Nuclear Medicine

10.3.1.2.3. By Therapeutic Nuclear Medicine

10.3.1.2.4. By Application

10.3.1.2.5. By End User

10.3.2. Colombia Nuclear Medicine market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type

10.3.2.2.2. By Diagnostic Nuclear Medicine

10.3.2.2.3. By Therapeutic Nuclear Medicine

10.3.2.2.4. By Application

10.3.2.2.5. By End User

10.3.3. Argentina Nuclear Medicine market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type

10.3.3.2.2. By Diagnostic Nuclear Medicine

10.3.3.2.3. By Therapeutic Nuclear Medicine

10.3.3.2.4. By Application

10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Nuclear Medicine market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Cardinal Health, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Curium SAS

15.3. GE Healthcare, Inc.

15.4. Novartis AG

15.5. Lantheus Medical Imaging, Inc.

15.6. Bayer AG

15.7. Bracco Imaging S.p.A

15.8. Nordion Inc.

15.9. Isotopia Molecular Imaging Limited

15.10. NorthStar Medical Radioisotopes, LLC

16. Strategic Recommendations

17. About Us & Disclaimer

Figures and Tables

Figure 1: Global Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 3: Global Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 4: Global Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 5: Global Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 6: Global Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 7: Global Nuclear Medicine Market Share, By Region, By Value, 2017-2027F

Figure 8: Global Nuclear Medicine Market Share, By Company, By Value, 2021

Figure 9: Global Nuclear Medicine Market Map, By Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 10: Global Nuclear Medicine Market Map, By Application, Market Size (USD Million) & Growth Rate (%), 2021

Figure 11: Global Nuclear Medicine Market Map, By End User, Market Size (USD Million) & Growth Rate (%), 2021

Figure 12: Global Nuclear Medicine Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 13: North America Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 14: North America Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 15: North America Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 16: North America Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 17: North America Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 18: North America Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 19: North America Nuclear Medicine Market Share, By Country, By Value, 2017-2027F

Figure 20: United States Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 21: United States Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 22: United States Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 23: United States Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 24: Canada Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 25: Canada Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 26: Canada Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 27: Canada Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 28: Mexico Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 29: Mexico Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 30: Mexico Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 31: Mexico Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 32: Europe Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 33: Europe Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 34: Europe Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 35: Europe Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 36: Europe Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 37: Europe Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 38: Europe Nuclear Medicine Market Share, By Country, By Value, 2017-2027F

Figure 39: Germany Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 40: Germany Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 41: Germany Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 42: Germany Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 43: France Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 44: France Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 45: France Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 46: France Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 47: United Kingdom Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 48: United Kingdom Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 49: United Kingdom Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 50: United Kingdom Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 51: Italy Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 52: Italy Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 53: Italy Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 54: Italy Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 55: Spain Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 56: Spain Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 57: Spain Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 58: Spain Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 59: Asia Pacific Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 60: Asia Pacific Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 61: Asia Pacific Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 62: Asia Pacific Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 63: Asia Pacific Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 64: Asia Pacific Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 65: Asia Pacific Nuclear Medicine Market Share, By Country, By Value, 2017-2027F

Figure 66: China Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 67: China Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 68: China Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 69: China Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 70: Japan Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 71: Japan Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 72: Japan Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 73: Japan Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 74: India Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 75: India Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 76: India Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 77: India Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 78: Australia Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 79: Australia Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 80: Australia Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 81: Australia Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 82: South Korea Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 83: South Korea Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 84: South Korea Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 85: South Korea Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 86: South America Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 87: South America Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 88: South America Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 89: South America Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 90: South America Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 91: South America Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 92: South America Nuclear Medicine Market Share, By Country, By Value, 2017-2027F

Figure 93: Brazil Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 94: Brazil Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 95: Brazil Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 96: Brazil Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 97: Argentina Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 98: Argentina Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 99: Argentina Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 100: Argentina Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 101: Colombia Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 102: Colombia Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 103: Colombia Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 104: Colombia Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 105: Middle East & Africa Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 106: Middle East & Africa Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 107: Middle East & Africa Nuclear Medicine Market Share, By Type, By Diagnostic Nuclear Medicine, By Value, 2017-2027F

Figure 108: Middle East & Africa Nuclear Medicine Market Share, By Type, By Therapeutic Nuclear Medicine, By Value, 2017-2027F

Figure 109: Middle East & Africa Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 110: Middle East & Africa Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 111: Middle East & Africa Nuclear Medicine Market Share, By Country, By Value, 2017-2027F

Figure 112: South Africa Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 113: South Africa Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 114: South Africa Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 115: South Africa Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 116: UAE Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 117: UAE Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 118: UAE Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 119: UAE Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

Figure 120: Saudi Arabia Nuclear Medicine Market Size, By Value (USD Million), 2017-2027F

Figure 121: Saudi Arabia Nuclear Medicine Market Share, By Type, By Value, 2017-2027F

Figure 122: Saudi Arabia Nuclear Medicine Market Share, By Application, By Value, 2017-2027F

Figure 123: Saudi Arabia Nuclear Medicine Market Share, By End User, By Value, 2017-2027F

List of Tables

Table 1: Global Cancer Statistics, 2020

Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020

Table 3: North America Cancer Statistics, 2020

Table 4: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020

Table 5: Europe Cancer Statistics, 2020

Table 6: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020

Table 7: Asia-Pacific Cancer Statistics, 2020

Table 8: Total Number of New Cancer Cases and Deaths Reported in Asia-Pacific, By Type, 2020

Table 9: South America Cancer Statistics, 2020

Table 10: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020

Table 11: Middle East & Africa Cancer Statistics, 2020

Table 12: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Nuclear Medicine market in 2025?

Which is the dominating region in the Global Nuclear Medicine market?

Which is the fastest growing segment in the Global Nuclear Medicine market?

What is the expected growth rate of the Global Nuclear Medicine market?